deanol aceglumate

Nooclerin (deanol aceglumate) is a nootropic agent developed by PIQ-Pharma Group, chemically composed of deanol (2-dimethylaminoethanol) and N-acetyl-L-glutamic acid. It is primarily indicated for the treatment of asthenic disorders and cognitive impairments, including those in pediatric populations such as developmental delays or attention deficit disorders. The drug's mechanism of action involves increasing the levels of acetylcholine in the brain, as deanol serves as a precursor, and modulating glutamatergic neurotransmission through the N-acetyl-L-glutamate component. This dual action helps improve memory, concentration, and mental performance while reducing fatigue and emotional lability. It is approved for use in Russia and is typically administered as an oral solution.

Brand names

Nooclerin

Other names

Deanol N-acetylglutamateN-acetyl-L-glutamic acid compound with 2-(dimethylamino)ethanol